ARID1B
ARID1B (AT-rich interactive domain-containing protein 1B) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Colorectal cancer, Renal cell carcinoma and 5 more.
Overview
Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Component of SWI/SNF chromatin remodeling complexes that carry out key enzymatic activities, changing chromatin structure by altering DNA-histone contacts within a nucleosome in an ATP-dependent manner. Belongs to the neural progenitors-specific chromatin remodeling complex (npBAF complex) and the neuron-specific chromatin remodeling complex (nBAF complex).
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.76 (direct and indirect evidence; datatypes affected pathway 0.29, literature 0.94, genetic association 0.30, somatic mutation 0.95, animal model 0.46). IntOGen calls it a driver in 22 cohorts (4 activating, 16 loss-of-function), covering Angiosarcoma, Bladder Urothelial Carcinoma, Invasive Breast Carcinoma, Renal Clear Cell Carcinoma, Cervical Adenocarcinoma, Colorectal Adenocarcinoma and others.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · ARID1B (AT-rich interactive domain-containing protein 1B) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Colorectal cancer, Renal cell carcinoma and 5 more.
- 1 · What it is
ARID1B (AT-rich interactive domain-containing protein 1B) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Colorectal cancer, Renal cell carcinoma and 5 more.
- 2 · What goes wrong in cancer
Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology).
- 3 · How drugs use it
No product in this corpus aims at ARID1B yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:18040 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q8NFD5 (protein name, function text, keywords and locations (REST API)); CIViC gene ARID1B (1 evidence items, 0 assertions, 1 variants; diseases: (GraphQL API, CC0)); Open Targets ENSG00000049618 (association with cancer (MONDO_0004992) 0.76; per-cancer scores at or above 0.5: colorectal cancer 0.56, ovarian cancer 0.55, endometrial cancer 0.53, melanoma 0.55, skin cancer 0.56, breast cancer 0.59 (GraphQL API, CC0)); IntOGen ARID1B (driver in 22 cohorts (Act 4, LoF 16); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Component of SWI/SNF chromatin remodeling complexes that carry out key enzymatic activities, changing chromatin structure by altering DNA-histone contacts within a nucleosome in an ATP-dependent manner. Belongs to the neural progenitors-specific chromatin remodeling complex (npBAF complex) and the neuron-specific chromatin remodeling complex (nBAF complex). During neural development a switch from a stem/progenitor to a postmitotic chromatin remodeling mechanism occurs as neurons exit the cell cycle and become committed to their adult state. The transition from proliferating neural stem/progenitor cells to postmitotic neurons requires a switch in subunit composition of the npBAF and nBAF complexes. As neural progenitors exit mitosis and differentiate into neurons, npBAF complexes which contain ACTL6A/BAF53A and PHF10/BAF45A, are exchanged for homologous alternative ACTL6B/BAF53B and DPF1/BAF45B or DPF3/BAF45C subunits in neuron-specific complexes (nBAF). Location: Nucleus (UniProt). Locus 6q25.3 (HGNC).
- Breast cancer: Open Targets association 0.59 with breast cancer (MONDO_0007254); IntOGen driver in 1 cohort (BRCA)
- Colorectal cancer: Open Targets association 0.56 with colorectal cancer (MONDO_0005575); IntOGen driver in 2 cohorts (COADREAD)
- Renal cell carcinoma: IntOGen driver in 2 cohorts (CCRCC, PRCC)
- Endometrial cancer: Open Targets association 0.53 with endometrial cancer (MONDO_0011962); IntOGen driver in 1 cohort (UCEC)
- Bladder & urothelial cancer: IntOGen driver in 1 cohort (BLCA)
- Cervical cancer: IntOGen driver in 1 cohort (CEAD)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 4 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 16 cohorts; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Low-Grade Glioma, NOS.
Latest papers
topQuery for this target: (TITLE:"ARID1B" OR ABSTRACT:"ARID1B" OR TITLE:"AT-rich interaction domain 1B" OR ABSTRACT:"AT-rich interaction domain 1B" OR TITLE:"AT-rich interactive domain-containing protein 1B" OR ABSTRACT:"AT-rich interactive domain-containing protein 1B" OR TITLE:"KIAA1235" OR ABSTRACT:"KIAA1235" OR TITLE:"ELD/OSA1" OR ABSTRACT:"ELD/OSA1" OR TITLE:"p250R" OR ABSTRACT:"p250R") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ARID1B, not a curated reading list.